HEALTH

J&J chief: McNeil will work to reclaim marketshare this year

BY Michael Johnsen

NEW BRUNSWICK, N.J. — Johnson & Johnson expects to return about 75% of its OTC brands to the marketplace over the course of 2013, Alex Gorsky, J&J chairman and CEO told analysts Tuesday. "I’m very pleased with the progress that we’re making in that," he said. "We mentioned to you that the consent decree that we had designed in conjunction with the FDA was approved and reviewed in October, with very few comments. And given the breadth and scale of that agreement, we felt very good about that. We’ve had teams working hard since then. We’ve achieved all of our major milestones since we’ve submitted that agreement."

Over the past six months, J&J’s OTC division McNeil Consumer Health has been bringing brands like Children’s Tylenol and Children’s Motrin back to market. "If you look at some of the consumer ratings, the quality of those brands, we’ve seen them [as] remarkably resilient through this period," Gorsky said. "And when we get them back to the market, we see an uptake occur."

Leading the charge in managing McNeil’s comeback is Sandy Peterson, who assumed her role last month. "[She] is focusing on returning our consumer segment to growth together with Jesse Wu, our worldwide chairman of the consumer group and his leadership team," Gorsky said. 

In addition to ensuring that there is adequate supply to feed the mass retail supply chain, McNeil in 2013 will begin to shift its focus on relaunching the brands "working with our trade partners, working with our great marketing teams, to reestablish those brands and their leadership positions in the market," Gorsky said. "And we’ll do that as the brands reenter over the course of 2013."


Find us on Facebook for more insight, analysis and the latest in drug store news.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
HEALTH

Perrigo launches private label equivalent to Nicorette mini lozenge

BY Michael Johnsen

ALLEGAN, Mich. — Perrigo on Tuesday announced that it has begun shipments of over-the-counter nicotine polacrilex mini lozenge USP, 2 mg (mint flavor) and 4 mg (mint flavor), comparable to GlaxoSmithKline’s Nicorette mini lozenge. 

"This launch strengthens Perrigo’s leading store brand position in smoking cessation products, which also includes coated and uncoated flavored gums and regular size lozenges," stated Joseph Papa, Perrigo’s chairman, president and CEO. 

Nicorette Mini Lozenge is selling at an annual rate estimated at more than $30 million at all retail outlets, Perrigo stated.


Find us on Facebook for more insight, analysis and the latest in drug store news.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
HEALTH

J&J introduces innovation to diabetes diagnostics and insulin delivery space

BY Michael Johnsen

NEW YORK — During its annual business review Tuesday, Johnson & Johnson announced that the recent introduction of the OneTouch Verio Glucose testing platform represented one of the first diabetes care devices to alert and display high/low patterns that deliver more meaningful and actionable insights to help patients better understand and manage their diabetes.

Also, recently acquired Calibra Medical expanded the J&J’s Global Medical Solutions portfolio of insulin delivery innovations with a unique "wearable" insulin patch, which when it is introduced, will make it easier for patients who need an easy-to-administer, meal-time dosing solution.

"Our [medical devices and diagnostics] business is the largest medical technology business in the world with sales of $27.4 billion, which grew 8.7% operationally," stated Alex Gorsky, J&J chairman and CEO. "We’re building on our market leadership positions, having sustained or grown share in the majority of our key platforms, and hold No. 1 or No. 2 positions in over 80% of them today."

Medical devices and diagnostics accounted for about 41% of Johnson & Johnson’s total sales in 2012.


Find us on Facebook for more insight, analysis and the latest in drug store news.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?